Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01708889 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal Dysfunction
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
NCT01708889: Completed Phase 1 study, sponsored by Bristol-Myers Squibb.
NCT01708889 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 43 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (28% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01708889, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effect of renal impairment on pharmacokinetics (PK) of BMS-914143.
Interventions
- BIOLOGICAL BMS-914143 (Peginterferon Lambda-1a)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2012-09 |
| Est. Completion | 2013-02 |
| Phase | Phase 1 |
What the finished NCT01708889 record still lists
NCT01708889 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (28% lower).
The record links to 0 conditions, and to 1 intervention - of which BMS-914143 (Peginterferon Lambda-1a) is the first listed.
NCT01708889 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01708889 about?
NCT01708889 is a clinical study titled "Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal Dysfunction". The purpose of this study is to determine the effect of renal impairment on pharmacokinetics (PK) of BMS-914143.
What is the current status of trial NCT01708889?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2012-09. Estimated completion is 2013-02.
What interventions are being tested in trial NCT01708889?
The interventions under investigation include: BMS-914143 (Peginterferon Lambda-1a) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01708889?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01708889's enrollment target sits among peer trials
43 1100th of 2000 higher than 896 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia